Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.22.1
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the three months ending March 31, 2022 and 2021:

Three Months Ended March 31, 

    

2022

    

2021

Revenue

Targadox®

$

2,634

$

7,199

Ximino®

967

2,100

Exelderm®

704

1,217

Accutane®

4,907

196

Qbrexza®

7,376

Amzeeq®

3,466

Zilxi®

741

Other branded revenue

1

7

Collaboration revenue

577

800

Revenue – related party

 

52

 

68

Other revenue

2,500

 

Net revenue

$

23,925

$

11,587